WX ==> The Mojeaux's Winner

[riverbabe]

http://www.wuxiapptec.com/career_opportunities.html

Well...they are still hiring abundantly, which indicates to me they see good cash flows going forward.

That is impressive! Thank you.

[mrmarket]

WuXi PharmaTech Announces Second-Quarter 2014 Results

WuXi PharmaTech18 hours ago













SHANGHAI, Aug. 13, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (WX), a leading research and development services company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States, today announced its financial results for the second quarter of 2014.
Second-Quarter 2014 Highlights

• Net Revenues Increased 14.8% Year Over Year to $163.4 Million
• Laboratory Services Net Revenues Grew 13.2% Year Over Year to $119.9 Million
• China-Based Laboratory Services Net Revenues Increased 14.2% Year Over Year to $95.2 Million
• U.S.-Based Laboratory Services Net Revenues Grew 9.6% Year Over Year to $24.7 Million
• Manufacturing Services Net Revenues Increased 19.3% Year Over Year to $43.5 Million
• GAAP Diluted Earnings Per ADS Remained Unchanged Year Over Year at $0.41
• Non-GAAP Diluted Earnings Per ADS Increased 5.2% Year Over Year to $0.49
• Full-Year 2014 Revenue and Diluted EPS Guidance Increased

Management Comment
"WuXi PharmaTech had another solid performance in the second quarter," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "We achieved record quarterly revenues, led by small-molecule manufacturing and biologics. Our revenue growth was broad-based, with 19.3%, 14.2%, and 9.6% year-over-year growth in Manufacturing Services, China Lab Services, and U.S. Lab Services, respectively, and we exceeded our second-quarter guidance in revenues.
"We also had a good quarter in profitability, exceeding our second-quarter guidance for non-GAAP diluted EPS and achieving the top of our guidance range for GAAP diluted EPS," Dr. Li continued. "Gross margin in the second quarter reflected year-over-year improvement of more than one full percentage point, driven by productivity initiatives, effective cost control, and the favorable impact of a depreciated RMB. We are using our free cash flow to reinvest in our business as we build new capabilities in manufacturing, biologics, genomics, cell therapy, sales and marketing, information technology, and other areas. We also purchased $66 million of our stock in the second quarter.
Our strong second-quarter performance gives us confidence about our performance for the remainder of the year. We expect to sustain strong revenue growth in the second half of 2014, as we capitalize on the growing late-stage and commercial product pipeline in small-molecule manufacturing, the ramp-up of our biologics manufacturing business, and investments in new businesses. We raise our full-year 2014 revenue guidance range from the previous $660-$670 million to $665-$670 million and increase our guidance for full-year 2014 GAAP and non-GAAP diluted EPS.
"We remain committed to building the premier open-access R&D platform that enables anyone and any company to discover and develop innovative medicines to benefit the world's patients," Dr. Li concluded.
Second-Quarter 2014 GAAP Results
Second-quarter 2014 net revenues increased 14.8% year over year to $163.4 million. Revenue growth in Laboratory Services of 13.2% was driven by our comprehensive and integrated drug discovery and development services. Revenue growth of 19.3% in Manufacturing Services was caused by strong demand in both research manufacturing and commercial manufacturing compared to the second quarter of 2013.
Second-quarter 2014 GAAP gross profit increased 18.9% year over year to $61.5 million due to 14.8% revenue growth and productivity improvement. Gross margin increased year over year to 37.7% from 36.4% mainly due to improved productivity, the ramp-up of biologics services, and the favorable impact of a depreciated RMB versus the U.S. dollar, partially offset by increased labor costs in China. Gross margin in Manufacturing Services increased year over year to 31.7% from 29.1%. Gross margin in Laboratory Services increased year over year to 39.8% from 38.9%.
Second-quarter 2014 GAAP operating income increased 9.0% year over year to $28.0 million due to the 18.9% increase in gross profit, partially offset by increased general and administrative expenses, including hiring of senior management, and R&D expenses in biologics, discovery biology, genomics, and other areas. Operating margin declined to 17.1% from 18.1% due to these increased general and administrative and R&D expenses, partially offset by the impact of a depreciated RMB versus the U.S. dollar, which is favorable because a large majority of our revenues are denominated in U.S. dollars and most of our expenses are denominated in RMB.
Second-quarter 2014 GAAP net income decreased 1.0% year over year to $29.3 million due to mark-to-market losses on foreign-exchange forward contracts of $2.5 million, compared to mark-to-market gains of $3.0 million in the second quarter of 2013, and a higher effective tax rate compared to the second quarter of 2013 due to the mix of taxable income and a $1.1 million one-time tax refund received in second-quarter 2013, partially offset by the 9.0% year-over-year increase in operating income, a $2.2 million gain on the sale of an investment by the corporate venture fund, smaller equity-method investment losses from our joint ventures with PRA and MedImmune and other equity-method investments, and higher interest income due to higher cash balances and higher interest rates. Realized gains on settled foreign-exchange forward contracts were $1.6 million in the second quarter of 2014.
Second-quarter 2014 GAAP diluted earnings per ADS remained unchanged at $0.41 due to the 1.0% decrease in net income, offset by a lower number of outstanding ADSs as a result of share purchases. Second-quarter 2014 GAAP comprehensive income decreased 35.4% year over year to $24.1 million due to the 1.0% decrease in GAAP net income and unfavorable currency translation adjustments, offset by unrealized gains on available-for-sale securities.
Second-Quarter 2014 Non-GAAP Results
Non-GAAP financial results exclude the impact of share-based compensation expenses and the amortization of acquired intangible assets and the associated deferred tax impact.
Second-quarter 2014 non-GAAP gross profit increased 19.3% year over year to $63.2 million due to the 14.8% revenue growth and productivity improvement. Non-GAAP gross margin increased year over year to 38.7% from 37.2% due to improved productivity, the ramp-up of biologics services, and the favorable impact of a depreciated RMB versus the U.S. dollar, offset by increased labor costs in China.
Second-quarter 2014 non-GAAP operating income increased 13.8% year over year to $33.9 million due to the 19.3% increase in non-GAAP gross profit, partially offset by increased general and administrative expenses, including hiring of senior management, and R&D expenses in biologics, discovery biology, genomics, and other areas. Non-GAAP operating margin decreased slightly to 20.8% from 20.9% due to increased general and administrative and R&D expenses, offset by the favorable impact of a depreciated RMB versus the U.S. dollar.
Second-quarter 2014 non-GAAP net income increased 4.5% year over year to $35.2 million due to the 13.8% year-over-year increase in non-GAAP operating income, a $2.2 million gain on the sale of an investment by the corporate venture fund, smaller equity-method investment losses from our joint ventures with PRA and MedImmune and other equity-method investments, and higher interest income due to higher cash balances and higher interest rates, partially offset by mark-to-market losses on foreign-exchange forward contracts of $2.5 million, compared to mark-to-market gains of $3.0 million in the second quarter of 2013, and a higher effective tax rate compared to the second quarter of 2013 due to the mix of taxable income and a $1.1 million one-time tax refund received in second-quarter 2013. Realized gains on settled foreign-exchange forward contracts were $1.6 million in the second quarter of 2014.
Second-quarter 2014 non-GAAP diluted earnings per ADS increased 5.2% year over year to $0.49 due to the 4.5% increase in non-GAAP net income and a lower number of outstanding ADSs as a result of share purchases.
Full-Year 2014 Financial Guidance
WuXi PharmaTech updates its full-year 2014 financial guidance:

• Total net revenues of $665-$670 million, compared to previous guidance of $660-$670 million
• GAAP diluted earnings per ADS of $1.55-$1.59, compared to previous guidance of $1.53-$1.58
• Non-GAAP diluted earnings per ADS of $1.82-$1.86, compared to previous guidance of $1.80-$1.85
• Capital expenditures of $95-$100 million, compared to previous guidance of about $85 million, driven primarily by capacity expansion in small-molecule manufacturing and investment in laboratories and technology in genomics, biologics, and biology

Third-Quarter 2014 Financial Guidance
WuXi PharmaTech provides the following third-quarter 2014 financial guidance:

• Total net revenues of $171-$173 million
• GAAP diluted earnings per ADS of $0.40-$0.42
• Non-GAAP diluted earnings per ADS of $0.48-$0.50

[tiedyed1]

Nice Q2 : WuXi PharmaTech beats by $0.03, beats on revs; guides Q3 EPS in-line, revs below consensus; raises FY14 earnings per ADS, above consensus, raises bottom end of revs guidance, in-line

Glad I doubled down when it was beat down and patience will payoff with this position

Keep on Keepin' HUGE Mr. Market!

[tiedyed1]

Up $2.96 (9.19%) today on heavy volume.
RSI significantly up.
All a good sign.

[mrmarket]

yeaaa.....buddy!!!


WuXi PharmaTech Announces Third-Quarter 2014 Results

WuXi PharmaTech (Cayman) Inc.November 12, 2014 4:30 PM

• 
• 
• 
• 

• [*=center]
  [*=center]
  [*=center]

SHANGHAI, Nov. 12, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States, today announced its financial results for the third quarter of 2014.
Third-Quarter 2014 Highlights

• Net Revenues Increased 18.3% Year Over Year to $173.6 Million
• Laboratory Services Net Revenues Grew 16.6% Year Over Year to $126.0 Million
• China-Based Laboratory Services Net Revenues Increased 18.2% Year Over Year to $100.5 Million
• U.S.-Based Laboratory Services Net Revenues Grew 10.8% Year Over Year to $25.5 Million
• Manufacturing Services Net Revenues Increased 22.9% Year Over Year to $47.6 Million
• GAAP Diluted Earnings Per ADS Grew 8.2% Year Over Year to $0.45
• Non-GAAP Diluted Earnings Per ADS Increased 13.8% Year Over Year to $0.54

Management Comment
"WuXi's strong momentum continued in the third quarter," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "We achieved 18% year-over-year revenue growth, led by small-molecule manufacturing and biologics. Manufacturing Services, China Lab Services, and U.S. Lab Services each achieved record quarterly revenues. The revenue growth was broad-based, with 23%, 18%, and 11% year-over-year growth in Manufacturing Services, China Lab Services, and U.S. Lab Services, respectively. We exceeded our third-quarter guidance in revenues, and we expect strong year-over-year revenue growth to continue in the fourth quarter.
"Our GAAP and non-GAAP diluted EPS grew 8% and 14%, respectively, both exceeding our third-quarter guidance," Dr. Li continued. "GAAP gross profit increased 26%, driven by strong revenue growth and productivity improvement. We achieved realized and unrealized gains from our hedging program and an appreciating RMB, as well as a gain from the sale of an investment by our venture fund.
"While achieving this solid revenue and diluted EPS growth, we continued to invest in new capabilities, including talent, laboratories, and technologies, particularly in manufacturing, biologics, genomics, R&D, sales and marketing, and information technology, to drive future revenue growth. Our largest current investment is a two-year, $100 million expansion of our manufacturing facilities in Changzhou that will double our current capacity and meet growing demand in both research manufacturing and commercial manufacturing. We are on track to have the new facilities come on line by the end of 2015.
"At the end of September, we acquired XenoBiotic Laboratories, Inc., a contract research organization located in Plainsboro, New Jersey, and Nanjing, China. The acquisition bolsters WuXi's Laboratory Testing Division in bioanalytical and DMPK/ADME services, particularly in studies of radio-labeled compounds, provides greater flexibility in service and support options for our North American customers, and gains access to new generic, agricultural, and animal health customers. WuXi will begin to reflect results of operations for XenoBiotic in the fourth quarter. The transaction is expected to be neutral to WuXi's 2014 diluted EPS and accretive to our 2015 diluted EPS on a non-GAAP basis. Reflecting the contribution of this acquisition, we are increasing our full-year revenue guidance to $670-$672 million.
"We continue to believe that our future is bright," Dr. Li concluded. "We expect particularly strong growth in small-molecule manufacturing and biologics for the next several years, as we capitalize on the growing late-stage and commercial product pipeline in small-molecule manufacturing and the ramp-up of our biologics manufacturing business. We remain focused on our mission to build the premier open-access R&D platform that enables anyone and any company to discover and develop innovative medicines to benefit the world's patients."

[tiedyed1]

Hello old friend WX. It has almost been a year but great to see you!
In fact, is that a $46 buyout offer I see today?
Are you trading at $45.80 before the market opens?
Why YES, you are, which means you are now #55 for Mr. Market's consecutive winners!!!

THE HUGE ONE DOES IT AGAIN.

Keep On Keepin' On; -Adam

[mrmarket]

why yes...yes indeed. It's all about the earnings...earnings...earnings!

[jiesen]

Didn't realize the buyout offer happened, and at $46 no less. All I saw was a 13% jump and a chance to sell for $45, which I did! Guess I might have had another buck if I bothered to read the news, but I'm quite happy with my 17% gain on this one. Thanks for this awesome pick, $$MM!! You are HUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUGGGEEEE!!!!

[tiedyed1]

It is a proposal presented to purchase at $46, but subject to committee analysis and review.
Good job getting out early today too!
All good as showing the strength in the company and catapulting it to #55 for Mr. Market.